clinical trial · NCT07624071
A Study to Evaluate ALN-6222 in Participants With Obesity
ObesityALN-6222Placebo
brief summary
This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.
started
Jun 3, 2026
primary completion
Dec 14, 2027
completion
Dec 14, 2027
last updated
Jun 3, 2026
official title
A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ALN-6222 in Adult Participants With Obesity
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol